High‐throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide‐3‐kinase and other oncogenes

The identification of new genes that are mutated in osteosarcomas is critical to developing a better understanding of the molecular pathogenesis of this disease and discovering new targets for therapeutic development.

[1]  A. D. Van den Abbeele,et al.  Major response to imatinib mesylate in KIT-mutated melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Freeman,et al.  Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. , 2009, International journal of oncology.

[3]  R. Gorlick,et al.  Chemotherapy resistance in osteosarcoma: current challenges and future directions , 2006, Expert review of anticancer therapy.

[4]  M. Ladanyi,et al.  Mechanisms of methotrexate resistance in osteosarcoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  David M. Thomas,et al.  Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis , 2010, Clinical Cancer Research.

[6]  A. Huvos,et al.  Frequent amplification and rearrangement of chromosomal bands 6p12‐p21 and 17p11.2 in osteosarcoma , 2004, Genes, chromosomes & cancer.

[7]  H. Abelson,et al.  Adjuvant chemotherapy for osteosarcoma: a decade of experience. , 1981, The Surgical clinics of North America.

[8]  Tesshi Yamada,et al.  Functional genome screen for therapeutic targets of osteosarcoma , 2009, Cancer science.

[9]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[10]  P. Houghton,et al.  Fully Human Monoclonal Antibody Targeting IGF-1 R , Is Effective Alone and in Combination With Rapamycin in Inhibiting Growth of Osteosarcoma Xenografts , 2010 .

[11]  R. Gorlick.  Current concepts on the molecular biology of osteosarcoma. , 2010, Cancer treatment and research.

[12]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[13]  H. Mankin,et al.  Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. , 2010, Cancer letters.

[14]  R. Gorlick.  Osteosarcoma: clinical practice and the expanding role of biology. , 2002, Journal of musculoskeletal & neuronal interactions.

[15]  Shishir Shah,et al.  Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma , 2004, BMC Cancer.

[16]  L. Garraway,et al.  Clinical implications of the cancer genome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Mankin,et al.  Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer , 2008, Molecular Cancer Therapeutics.

[18]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[19]  M. Ladanyi,et al.  Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. , 2003, Human molecular genetics.

[20]  W. Winkelmann,et al.  Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome , 2007, Clinical Cancer Research.

[21]  R. Chugh.  Experimental therapies and clinical trials in bone sarcoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  S. Do,et al.  The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. , 2009, International journal of oncology.

[23]  M. Gebhardt,et al.  Biology and therapeutic advances for pediatric osteosarcoma. , 2004, The oncologist.

[24]  Jing Ma,et al.  Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors , 2008, Cancer.

[25]  B. Peters,et al.  Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. , 2007, Human pathology.

[26]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[27]  H. Mankin,et al.  Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines , 2009, Molecular Cancer Therapeutics.

[28]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[29]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[30]  Keith L. Ligon,et al.  Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples , 2009, PloS one.

[31]  Z. Duan,et al.  Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway , 2010, BMC Cancer.

[32]  A. Davis,et al.  Prognostic factors in osteosarcoma: a critical review. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Kyung S. Lee,et al.  A Spindle Checkpoint Arrest and a Cytokinesis Failure by the Dominant-negative Polo-box Domain of Plk1 in U-2 OS Cells* 210 , 2002, The Journal of Biological Chemistry.

[34]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[35]  M. Gebhardt,et al.  Survival Data for 648 Patients with Osteosarcoma Treated at One Institution , 2004, Clinical orthopaedics and related research.

[36]  R. Gorlick,et al.  Novel therapeutic agents for osteosarcoma , 2009, Expert review of anticancer therapy.

[37]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[38]  R. Gorlick,et al.  Osteosarcoma: a review of diagnosis, management, and treatment strategies. , 2010, Clinical advances in hematology & oncology : H&O.

[39]  G. Shapiro,et al.  Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer , 2010, Current oncology reports.

[40]  Derek Y. Chiang,et al.  Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy , 2010, Nature Genetics.

[41]  T. Fan,et al.  Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs , 2010, PloS one.

[42]  William R. Sellers,et al.  PI3K/PTEN/Akt Pathway , 2004 .

[43]  Yong Zhu,et al.  mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis , 2010, Medical oncology.

[44]  A. Goorin,et al.  Current Treatment of Osteosarcoma , 2001, Cancer investigation.

[45]  P. Terrier,et al.  Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  William R Sellers,et al.  PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. , 2003, Cancer treatment and research.

[47]  A. Huvos,et al.  The patterns of relapse in osteosarcoma: The memorial Sloan‐Kettering experience , 2004, Pediatric blood & cancer.

[48]  H. Mankin,et al.  Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated‐Stat3 correlates with poor prognosis , 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[49]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.